特立帕肽
医学
骨质疏松症
德诺苏马布
药品
重症监护医学
药理学
内科学
骨矿物
作者
Mika Yamauchi,Toshitsugu Sugimoto
出处
期刊:PubMed
[National Institutes of Health]
日期:2015-09-01
卷期号:25 (9): 1285-92
被引量:4
摘要
The main revisions to the item of medical treatment in the 2015 edition of the Guidelines for Prevention and Treatment of Osteoporosis are the additions of the drugs such as ibandronate, teriparatide acetate (once-weekly preparation), and denosumab, which were approved after the release of the 2011 edition, and of information on new dosage forms for existing drugs. Furthermore, the heading "Evaluation and Recommendations" for each drug was changed to "Evaluation of Efficacy" . The choice of drug is determined based on evidence for the effectiveness of each drug and in accordance with the age, fracture risk, and pathophysiology of each patient. As for the selection and combined use of the various drugs, accumulation of evidence is anticipated, but sequential therapy using antiresorptive agents following treatment with teriparatide preparations is recommended.
科研通智能强力驱动
Strongly Powered by AbleSci AI